Ratings Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
0.5178 ^USD	+2.94%		+1.23%	-4.69%

22/03	Sangamo Therapeutics Prices $24 Million Registered Direct Offering	MT
14/03	Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an enterprise value anticipated at 4.01 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SANGAMO THERAPEUTICS, INC.	-4.69%	107M	C
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B	B+
ARGENX SE	+0.49%	22.15B	B
BIONTECH SE	-17.37%	21.02B	B+
GENMAB A/S	-8.54%	18.15B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.73B	A-
BEIGENE, LTD.	-14.85%	16.05B	B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B	C+
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes